← Back to Search

Behavioural Intervention

DepWatch for Depression (DepWatch Trial)

N/A
Recruiting
Led By Jayesh Kamath, MD PhD
Research Sponsored by UConn Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 years or older
Moderate level of depression as defined by a score of ≥ 11 on the 16 item Quick Inventory of Depressive Symptomatology (QIDS) self-report questionnaire
Must not have
Diagnosis of a primary psychotic disorder such as schizophrenia or schizoaffective disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 surveys conducted 4 months apart (over the 12 month study period)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to develop and test a new digital system called DepWatch that uses mobile health technologies and machine learning to help clinicians monitor and adjust depression treatment. The system collects data from smartphones and wristbands

Who is the study for?
This trial is for adults 18 years or older with moderate depression, starting new medication or increasing the dose of their current one. Participants must score ≥11 on a specific depression questionnaire (QIDS).
What is being tested?
The study tests 'DepWatch', an mHealth tool that tracks and predicts depression symptoms using data from smartphones and wristbands to help doctors make better treatment decisions.
What are the potential side effects?
Since DepWatch involves monitoring via mobile devices, side effects are not typical as with medications; however, participants may experience privacy concerns or stress related to constant data collection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have moderate depression based on a specific questionnaire score.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with a psychotic disorder like schizophrenia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 surveys conducted 4 months apart (over the 12 month study period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 surveys conducted 4 months apart (over the 12 month study period) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility and Usability
Secondary study objectives
Depression outcomes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: ExperimentalExperimental Treatment1 Intervention
For this group of participants: The study clinicians will receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch' via a secure clinician portal
Group II: ControlExperimental Treatment1 Intervention
For this group of participants: The study clinicians will NOT receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch'

Find a Location

Who is running the clinical trial?

UConn HealthLead Sponsor
212 Previous Clinical Trials
60,670 Total Patients Enrolled
10 Trials studying Depression
1,218 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,893 Previous Clinical Trials
2,722,649 Total Patients Enrolled
696 Trials studying Depression
260,668 Patients Enrolled for Depression
Jayesh Kamath, MD PhDPrincipal InvestigatorUConn Health
1 Previous Clinical Trials
6 Total Patients Enrolled
1 Trials studying Depression
6 Patients Enrolled for Depression
~58 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top